Ranked #7,878 of 8,699 institutional investors
Acuta Capital Partners, LLC
Redwood City, CA
$112M
US stock portfolio at live prices · today −$1.0M (−0.91%)
Live prices, last trade 10:36 AM ET
- Value at quarter end (Q3 2026)
- $130M
- Change from Q2 2026
- −$13.9M (−9.69%)
- Positions
- 32 · 9 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $2.0M of stock. $2.0M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPRAX 23.0%WHWK 12.9%TNGX 8.20%SLN 6.96%FDMT 5.09%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 84,193 | $25.8M | 23.0% | Added +2% |
| WHWK Whitehawk Therapeutics, Inc. | 4,685,912 | $14.5M | 12.9% | Unchanged |
| TNGX Tango Therapeutics, Inc. | 409,529 | $9.2M | 8.20% | Added +5% |
| SLN Silence Therapeutics plc | 393,583 | $7.8M | 6.96% | New |
| FDMT 4D Molecular Therapeutics, Inc. | 535,109 | $5.7M | 5.09% | Added +5% |
| ARGX argenx SE | 5,558 | $5.2M | 4.65% | Added +18% |
| SRZN Surrozen, Inc. | 152,541 | $4.5M | 4.05% | Reduced −12% |
| OCUL Ocular Therapeutix, Inc. | 574,543 | $3.3M | 2.96% | Added +8% |
| AVLN Avalyn Pharma Inc. | 114,749 | $3.2M | 2.87% | Reduced −0% |
| VOGX Vogenx, Inc. | 213,186 | $2.7M | 2.43% | New |
| TSHA Taysha Gene Therapies, Inc. | 691,843 | $2.6M | 2.30% | Added +23% |
| MLTX MoonLake Immunotherapeutics | 216,568 | $2.4M | 2.13% | Added +0% |
| IRLA IRulya Therapeutics Inc. | 52,918 | $2.2M | 1.93% | New |
| LBRX LB Pharmaceuticals Inc | 52,718 | $2.1M | 1.84% | Added +82% |
| IRD Opus Genetics, Inc. | 514,110 | $2.0M | 1.80% | New |
| DRUG Bright Minds Biosciences Inc. | 93,152 | $2.0M | 1.75% | Added +0% |
| AVBP ArriVent BioPharma, Inc. | 170,893 | $1.9M | 1.67% | Reduced −22% |
| AMLX Amylyx Pharmaceuticals, Inc. | 62,956 | $1.6M | 1.46% | Reduced −63% |
| NERV Minerva Neurosciences, Inc. | 729,500 | $1.5M | 1.36% | Added +3% |
| RVMD Revolution Medicines, Inc. | 8,237 | $1.4M | 1.21% | New |
| AVTX Avalo Therapeutics, Inc. | 186,308 | $1.3M | 1.13% | Unchanged |
| UTHR United Therapeutics Corporation | 2,240 | $1.2M | 1.11% | Added +1% |
| DSGN Design Therapeutics, Inc. | 115,392 | $1.1M | 0.96% | Reduced −59% |
| ARTV Artiva Biotherapeutics, Inc. | 260,416 | $993K | 0.89% | Unchanged |
| ERAS Erasca, Inc. | 67,541 | $927K | 0.83% | Reduced −75% |
| CTNM Contineum Therapeutics, Inc. | 89,826 | $797K | 0.71% | Added +42% |
| ANTX AN2 Therapeutics, Inc. | 142,051 | $742K | 0.66% | New |
| ORIC ORIC Pharmaceuticals, Inc. | 87,918 | $687K | 0.61% | New |
| STRO Sutro Biopharma, Inc. | 25,290 | $225K | 0.20% | Reduced −91% |
| EQ Equillium, Inc. | 183,000 | $209K | 0.19% | New |
| CMPX Compass Therapeutics, Inc. | 251,001 | $178K | 0.16% | Reduced −58% |
| STOK Stoke Therapeutics, Inc. | 5,771 | $157K | 0.14% | New |